Skip to main content

Advertisement

Table 1 Clinical findings at baseline and 6-month follow up in patients with psoriatic arthritis

From: Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score)

  Baseline visit (n =83) Follow up at 6 months (n =70) P-value
Age at inclusion, years 51.8 (11.7) n.a. n.a.
Female, n (%) 22 (26.2) n.a. n.a.
Body mass index, kg/m2‡ 27.2 (18.5 to 46.8) n.a. n.a.
Disease duration, years 7.5 (0 to 44.7) n.a. n.a.
Patients with a new diagnosis¥, n (%) 4 (4.8) n.a. n.a.
Axial involvement, n (%) 11 (13.3) n.a. n.a.
Smokers, n (%)   n.a. n.a.
Current 21 (25.3)
Previous 32 (38.6)
PASDAS‡ 5.9 (1.5) 5.2 (1.5) <0.001
DAPSA‡ 11.5 (0.1 to 70.2) 7.2 (0.1 to 73.5) 0.016
CPDAI‡ 3.0 (0 to 9.0) 2.0 (0 to 11.0) 0.019
CRP, mg/L ‡ 2.2 (0 to 49.5) 2.4 (0.2 to 35.0) n.s.
ESR, mm/1st hour‡ 9.5 (1 to 74) 10 (2 to 51) n.s.
TJ, 68-joint count‡ 4 (0 to 59) 1 (0 to 53) 0.012
SJ, 66-joint count‡ 1 (0 to 15) 0 (0 to 17) 0.011
PGA, mm† 31.2 (22.7) 21.3 (23.5) 0.073
Ptpain, mm† 30.5 (24.5) 20.7 (21.0) <0.001
EGA, mm† 22.0 (19.1) 11.5 (14.6) 0.009
HAQ† 0.7 (0.8) 0.6 (0.7) <0.001
BASDAI‡ 4.7 (0.9 to 5.5) 3.0 (0 to 6.0) n.s.
ASQol‡ 2.0 (0 to 11.0) 4.0 (0 to 8.0) n.s.
Leeds enthesitis score‡ 0 (0 to 4) 0 (0 to 2) n.s.
Dactylitis score‡ 0 (0 to 10) 0 (0 to 4) n.s.
PASI‡ 1.0 (0 to 23.2) 0.4 (0 to 36.3) n.s.
DLQI‡ 1.0 (0 to 20.0) 1.0 (0 to 18.0) n.s.
DMARDs, n (%)    n.s.
MTX 33 (39.8) 30 (42.9)
LFN 11 (13.3) 12 (17.1)
MTX + LFN 3 (3.6) 3 (4.3)
SSZ 2 (2.4) 2 (2.9)
Anti-TNFα 31 (37.3) 30 (42.9)
Corticosteroids, n (%) 6 (7.2) 4 (5.7) n.s.
NSAIDs, n (%)    n.s.
On demand 56 (67.5) 57 (81.4)
Regular intake 10 (12.0) 8 (11.4)
  1. Median (range); mean (standard deviation); P-values are not adjusted for multiple testing; ¥diagnosis was established at the day of baseline study visit. ASQol, ankylosing spondylitis quality of life; BASDAI, Bath ankylosing spondylitis disease activity index; CPDAI, composite psoriatic disease activity index; CRP, C-reactive protein (normal values 0 to 5 mg/L); DAPSA, disease activity index for psoriatic arthritis; DLQI, dermatology life quality index; DMARDs, disease-modifying anti-rheumatic drugs; EGA, evaluator’s global assessment of disease activity; ESR, erythrocyte sedimentation rate (normal values 1 to 10 mm/1st hour); HAQ, health assessment questionnaire; LFN, leflunomide; MTX, methotrexate; n, number; n.a., not applicable; n.s., not statistically significant; NSAIDs, non-steroidal anti-inflammatory drugs; PASDAS, psoriatic arthritis disease activity score; PASI, psoriasis area and severity index; PGA, patients’ global assessment of disease activity; Ptpain, patients’ pain assessment; SJ, swollen joint count; SSZ, sulfasalazine; TJ, tender joint count; TNF, tumour necrosis factor alpha. PGA, Ptpain and EGA were measured on visual analogue scales (range 0 to 100 mm) and are expressed in mm; BASDAI and ASQol values are shown for those 11 (13.3%) PsA patients with axial involvement.